Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients

Hashida,Shinsuke; Soh,Junichi; Toyooka,Shinichi; Tanaka,Tomoaki; Furukawa,Masashi; Shien,Kazuhiko; Yamamoto,Hiromasa; Asano,Hiroaki; Tsukuda,Kazunori; Hagiwara,Koichi; Miyoshi,Shinichiro

doi:10.3892/or.2014.3197

Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients

Authors:
- Shinsuke Hashida
- Junichi Soh
- Shinichi Toyooka
- Tomoaki Tanaka
- Masashi Furukawa
- Kazuhiko Shien
- Hiromasa Yamamoto
- Hiroaki Asano
- Kazunori Tsukuda
- Koichi Hagiwara
- Shinichiro Miyoshi
View Affiliations

Affiliations: Department of Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama 700-8558, Japan, Department of Respiratory Medicine, Saitama Medical University, Moroyama, Saitama 350-0495, Japan
Published online on: May 16, 2014 https://doi.org/10.3892/or.2014.3197
Pages: 145-152

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The T790M mutation in the epidermal growth factor receptor (EGFR) gene is known to be associated with the acquired resistance of lung adenocarcinoma patients to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). The minor T790M mutant allele is occasionally detected in EGFR-TKI-naive tumor samples, yet findings concerning the clinical impact of the minor T790M mutation vary among previous studies. In the present study, we assessed the clinical impact of the minor T790M mutation using a novel, highly sensitive assay combining high-resolution melting (HRM), mutant-enriched PCR and co-amplification at a lower denaturation temperature (COLD)-PCR. We determined the T790M mutational status in 146 surgically resected lung adenocarcinomas without a history of EGFR-TKI treatment using mutant-enriched COLD-HRM (MEC-HRM) and standard HRM assays. The sensitivities of the MEC-HRM and standard HRM assays for the detection of T790M-mutant alleles among wild-type alleles were 0.01 and 10%, respectively. Although the T790M mutation was not detected using a standard HRM assay, we identified 19 (13%) T790M mutations using the MEC-HRM assay and defined these 19 mutations as minor T790M mutations. The proportion of T790M alleles was <0.1% in 17 (84%) of the 19 samples. Multivariate analyses revealed that a minor T790M mutation was significantly associated with the presence of EGFR exon 19 deletions or the L858R mutation (both of which are drug-sensitive EGFR mutations) (P=0.04). In conclusion, the minor EGFR T790M mutations were present in 13% of EGFR-TKI-naive surgically resected lung adenocarcinomas and were associated with drug-sensitive EGFR mutations.

View Figures

View References

1	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
2	Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
3	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
4	Yamamoto H, Toyooka S and Mitsudomi T: Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer. 63:315–321. 2009.
5	Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar
6	Araki T, Yashima H, Shimizu K, et al: Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insights Oncol. 6:407–421. 2012. View Article : Google Scholar : PubMed/NCBI
7	Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar
8	Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 3:75ra262011. View Article : Google Scholar : PubMed/NCBI
9	Oxnard GR, Arcila ME, Sima CS, et al: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 17:1616–1622. 2011. View Article : Google Scholar : PubMed/NCBI
10	Eck MJ and Yun CH: Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta. 1804:559–566. 2010. View Article : Google Scholar : PubMed/NCBI
11	Maheswaran S, Sequist LV, Nagrath S, et al: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 359:366–377. 2008.
12	Inukai M, Toyooka S, Ito S, et al: Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66:7854–7858. 2006. View Article : Google Scholar : PubMed/NCBI
13	Oh JE, An CH, Yoo NJ and Lee SH: Detection of low-level EGFR T790M mutation in lung cancer tissues. APMIS. 119:403–411. 2011.PubMed/NCBI
14	Fujita Y, Suda K, Kimura H, et al: Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol. 7:1640–1644. 2012. View Article : Google Scholar
15	Rosell R, Molina MA, Costa C, et al: Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 17:1160–1168. 2011. View Article : Google Scholar
16	Su KY, Chen HY, Li KC, et al: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440. 2012.PubMed/NCBI
17	Toyooka S, Kiura K and Mitsudomi T: EGFR mutation and response of lung cancer to gefitinib. N Engl J Med. 352:21362005. View Article : Google Scholar : PubMed/NCBI
18	Sakuma Y, Yamazaki Y, Nakamura Y, et al: WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 92:371–383. 2012.PubMed/NCBI
19	Regales L, Gong Y, Shen R, et al: Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 119:3000–3010. 2009.PubMed/NCBI
20	Asano H, Toyooka S, Tokumo M, et al: Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res. 12:43–48. 2006.PubMed/NCBI
21	Li J, Wang L, Mamon H, Kulke MH, Berbeco R and Makrigiorgos GM: Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 14:579–584. 2008. View Article : Google Scholar : PubMed/NCBI
22	Luthra R and Zuo Z: COLD-PCR finds hot application in mutation analysis. Clin Chem. 55:2077–2078. 2009. View Article : Google Scholar : PubMed/NCBI
23	Milbury CA, Li J and Makrigiorgos GM: COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. Clin Chem. 55:2130–2143. 2009. View Article : Google Scholar : PubMed/NCBI
24	Song C, Milbury CA, Li J, Liu P, Zhao M and Makrigiorgos GM: Rapid and sensitive detection of KRAS mutation after fast-COLD-PCR enrichment and high-resolution melting analysis. Diagn Mol Pathol. 20:81–89. 2011. View Article : Google Scholar : PubMed/NCBI
25	Fan H and Gulley ML: DNA extraction from fresh or frozen tissues. Methods Mol Med. 49:5–10. 2001.PubMed/NCBI
26	Goto K, Satouchi M, Ishii G, et al: An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol. 23:2914–2919. 2012.
27	Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
28	Do H, Krypuy M, Mitchell PL, Fox SB and Dobrovic A: High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 8:1422008. View Article : Google Scholar : PubMed/NCBI
29	Ueno T, Toyooka S, Suda K, et al: Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer. 78:207–211. 2012. View Article : Google Scholar : PubMed/NCBI
30	Matsuo K, Ito H, Yatabe Y, et al: Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci. 98:96–101. 2007. View Article : Google Scholar : PubMed/NCBI
31	Bell DW, Gore I, Okimoto RA, et al: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 37:1315–1316. 2005. View Article : Google Scholar : PubMed/NCBI
32	Soh J, Okumura N, Lockwood WW, et al: Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 4:e74642009. View Article : Google Scholar : PubMed/NCBI
33	Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
34	Ohtsuka K, Ohnishi H, Kurai D, et al: Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation. J Clin Oncol. 29:e191–e192. 2011. View Article : Google Scholar : PubMed/NCBI
35	van Noesel J, van der Ven WH, van Os TA, et al: Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J Clin Oncol. 31:e161–e164. 2013.PubMed/NCBI
36	Chmielecki J, Foo J, Oxnard GR, et al: Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 3:90ra592011. View Article : Google Scholar : PubMed/NCBI
37	Govindan R, Ding L, Griffith M, et al: Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 150:1121–1134. 2012. View Article : Google Scholar : PubMed/NCBI